Abstract:Human epidermal growth factor receptor 2 (ERBB2, HER-2) 20 exon insertion (ERBB2ex20ins) has been identified as an oncogenic driver in lung cancer, for which no valid therapy is currently approved. Concurrent alterations may elucidate its refractory features. Previous studies on Afatinib, a pan-ERBB inhibitor, have revealed an inconsistent clinical activity of it for this group of patients. Plasma or tissue samples of 112 patients with ERBB2ex20ins were performed next generation sequencing (NGS) for 59 or 1021 cancer-related genes in a Clinical Laboratory Improvement Amendments-certified Laboratory from July 2016 to December 2018. The sequencing data of MSKCC Cohort was downloaded from the public Cancer Genome Atlas Database. The clinical outcomes of 18 patients receiving Afatinib treatment were collected by each contributing doctor in charge and pooled for analysis. Among the 112 patients, most of cases were female (54%, 60/112) and adenocarcinoma (68%, 76/112). Considering the insertions sites, three subtypes were A775ins (71%; 79/112), G776indel (17%; 19/112) and P780ins (12%; 14/112) in the order of frequency. 80.4% (90/112) of patients had at least one additional alteration. The most frequent co-occurring genes were TP53 (66.1%, 74/112), LRP1B (18.2%, 10/55), EPHA5 (9.1%, 5/55), MLL3 (9.1%, 5/55) and RB1 (8.0%; 9/112). Putative other driver aberrations were mutually exclusive from ERBB2ex20ins. Furthermore, cell cycle pathway was the most commonly involved pathway (84.0%; 94/112) of all the concurrent genes. No substantial differences of concurrence in genomic or pathway level were observed among the three ERBB2 insertion subtypes. The co-occurring genomic feature of ERBB2ex20ins in Our Cohort of Chinese people had an overall strong concordance with the MSKCC Cohort from the United States (R2=0.74, P<0.01). For the prognosis, patients had a worse OS when co-occurring mutation in TP53 [median OS:14.5m (95%CI: 12.7m-16.3m) vs 30.3m (95% CI: not reached)], while the OS was not significantly different among three subtypes. The median duration time for patients with disease control of Afatinib was 4.5 months (95%CI: 3.6m-5.4m; range: 2.5m-13.4m). Of note, ERBB2ex20ins in subclonal status was a significantly independent factor relating to shorter PFS of Afatinib [median PFS: 1.2m (95%CI: 0.8-1.6m) vs 4.3m (95%CI: 3.3m-5.3m), P<0.05]. Dynamic detection in two patients found ERBB2 amplification may be a resistance mechanism for Afatinib. Concurrence of genetic alterations in NSCLC patients with ERBB2ex20ins was common. The complex genomic characteristic should be fully considered by stratifying patients according to potentially relevant co-mutations other than ERBB2 insertion sites in the designing regimens for them. In addition, the therapeutic effect of Afatinib on patient with ERBB2ex20ins is limited, the clonal status of ERBB2ex20ins may be an important factor with prognosis value.

Real-World Large-Scale Study Of Erbb2 Gene Fusions And Its Response To Afatinib In Chinese Non-Small Cell Lung Cancer (Nsclc): A Multicenter Study.

A Multicenter Study of NRG1 Fusions in Chinese Non-Small Cell Lung Cancer Patients and Response to Afatinib Using Next Generation Sequencing

P1.01-126 the Co-Occurring Genomic Landscape of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib

Co-Occurring Alterations Of Erbb2 Exon 20 Insertion In Non-Small Cell Lung Cancer (Nsclc) And The Potential Indicator Of Response To Afatinib

Genomic Characterization and Outcome Evaluation of Kinome Fusions in a Large Non-Small Cell Lung Cancer Population.

Interim Analysis of Afatinib Monotherapy in Patients with Metastatic Nsclc Progressing after Chemotherapy and Erlotinib/Gefitinib (E/G) in A Trial of Afatinib Plus Paclitaxel Versus Investigator'S Choice Chemotherapy Following Progression on Afatinib Monotherapy

Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions

P2.06-013 Afatinib in Patients with Advanced HER2 Mutation-Positive (M+) NSCLC Previously Treated with Chemotherapy: Topic: Phase II + NK

Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients.

Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study

Clinical Characterization of ERBB2 Exon 20 Insertions and Heterogeneity of Outcomes Responding to Afatinib in Chinese Lung Cancer Patients

Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC

Prevalence of EGFR Gene Fusions in a Large Cohort of Chinese Patients with Non-Small Cell Lung Cancer (NSCLC).

Molecular and Clinicopathological Characteristics of ERBB2 Gene Fusions in 32,131 Chinese Patients with Solid Tumors.

[Afatinib Treatment for Advanced Mixed Non-small Cell Lung Cancer with CRISPLD2-NRG1 Fusion: A Case Report and Literature Review]

Real-world Data in Clinically Non-Small Cell Lung Cancer (NSCLC) with Chinese Population Harboring BRAF Gene Fusions: A Multicenter Study.

P1.01-61 Clinical Characterization of ERBB2 Exon 20 Insertions and Heterogeneity of Outcomes to Afatinib in Chinese Lung Cancers

P2.03-09 the Real World of NTRK Fusion Data in the Chinese Lung Cancer Populations: A Multicenter Study

OA07 Clinical Characterization of ERBB2 Exon 20 Insertions and Heterogeneity of Outcomes to Afatinib in Chinese Lung Cancers

clinical characterization of ERBB 2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in chinese lung cancer patients

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.